Comparison of products used in Hereditary Angioedema in the absence of Berinert

John Minshull, Deputy Director, London Medicines Information Service, Specialist Pharmacy ServiceSource London Medicines Information Service, London North West University Healthcare NHS TrustPublished

This table provides a summary of clinical factors to consider when using alternative complement regulatory proteins to Berinert (C1-esterase inhibitor).  Supplies of Berinert are expected to go out of stock and patients may need to be treated with Cinryze (C1-esterase inhibitor), Firazyr (Icatibant) , Takhzyro (Lanadelumab) or Ruconest (Conestat alfa).

Attachments